|
| Home : Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD) |
|
Mar 29
2022 |
Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD) |
|
Proceeds to be used for a phase 3 registration enabling trial with Lybrido. Funding from existing and new investors, reflecting great confidence in the candidate to be evaluated. FSIAD is a type of sexual dysfunction and a recognized unmet medical need with very limited effective... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/freya-pharma-solutions-secures-us8-5-million-enabling-the-start-of-a-pivotal-phase-3-trial-with-lybrido-against-female-sexual-interestarousal-disorder-fsiad-301512420.html |
| |
|
Related News
|
» ALLERGAN AESTHETICS BRINGS DATA, INNOVATION & INDUSTRY EXPERTISE TO THE 2022 AESTHETIC AND ANTI-AGING MEDICINE WORLD CONGRESS (AMWC)
» Global Solid Oxide Fuel Cell Market (SOFC) Size, Share, Demands, Key Players - Bloom Energy, Siemens Energy, Aisin Seiki, Mitsubishi Heavy Industries, Delphi Corp, GE, Convion, Fuel Cell Energy - ReportsnReports
|
|
|
